Langerhans cell histiocytosis: intrinsic immunoediting properties
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00085104" target="_blank" >RIV/00216224:14110/15:00085104 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Langerhans cell histiocytosis: intrinsic immunoediting properties
Original language description
Non-classical HLA-molecules physiologically protect the fetus from maternal allorecognition, this mechanism seems to be used by some tumors during their development. PD-L1 is physiologically expressed mainly on antigen presenting cells, some types of tumors use this ligand to supress host immune reactions. The expression of non-classical immunomodulatory molecules (HLA-G, HLA-E, HLA-F) as well as the expression of immune checkpoint regulator programmed death ligand (PD-L1) is not characterized in Langerhans cell histiocytosis (LCH). Our data suggest that non-classical immunomodulatory molecules and immune checkpoint molecules may play role in immunoediting process during development of LCH. Further studies regarding immunoediting properties including non-classical HLA molecules and immune checkpoints ligands appear warranted for better understanding and therapy of this enigmatic disorder.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů